AgeneBio Competitors and Similar CompaniesClear all
AgeneBio's competitors and similar companies include Supernus Pharmaceuticals, Shionogi, Alector and PharmatrophiX.
 AgeneBio AgeneBio is a pharmaceutical company dedicated to developing therapeutics that prevent neurodegeneration, preserve and restore cognitive brain function. |  Supernus Pharmaceuticals Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. |  Shionogi Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases. |  Alector Alector is a biotechnology company that develops therapies for the treatment of neurodegenerative diseases. |  PharmatrophiX PharmatrophiX is a company developing small molecule drugs for
neurodegenerative and other diseases. | |
Founding Date | Founding Date 2008 | Founding Date 2005 | Founding Date 1878 | Founding Date 2013 | Founding Date 2005 |
Type | Type Private | Type Public | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Baltimore, US HQ Baltimore, US | Locations Rockville, US HQ | Locations Osaka, JP HQ Beijing, CN Hong Kong, HK Amagasaki, JP Amagasaki, JP Kanegasaki, JP Misato, JP see more | Locations San Francisco, US HQ | Locations HQ |
Employees | Employees 4 | Employees 6527% increase | Employees 4,955 | Employees 2382% decrease | Employees N/A |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.9 b | Valuation ($) 12.3 b | Valuation ($) 495.3 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $719m (FY, 2025) | Revenue (est.) ¥499.7b (FY, 2026) | Revenue (est.) $21m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $74.6m (FY, 2025) | Cost of goods ¥55.5b (FY, 2026) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $644.4m (FY, 2025) | Gross profit ¥491.3b (FY, 2026) | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income ($38.6m) (FY, 2025) | Net income ¥205.9b (FY, 2026) | Net income ($142.9m) (FY, 2025) | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round $ 3.4m (over 6 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 10.3m (over 10 years ago) |
Total funding raised | Total funding raised $ 9.5m | Total funding raised $ 69.5m | Total funding raised $ 4.7m | Total funding raised $ 194.5m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Supernus Pharmaceuticals
HQ
Rockville, US
Employees
652↑ 7% increase
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders.
View companyShionogi
HQ
Osaka, JP
Employees
4,955
Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases.
View companyAlector
HQ
San Francisco, US
Employees
238↓ 2% decrease
Alector is a biotechnology company that develops therapies for the treatment of neurodegenerative diseases.
View companyPharmatrophiX
HQ
PharmatrophiX is a company developing small molecule drugs for neurodegenerative and other diseases.
View company